Сайт призначений виключно для фахівців охорони здоров'я в Україні

Шукати

Menu

Close

АвторизуватисяВийти
Наші препаратиТерапевтичні напрямиМатеріали і медіацентрМатеріали і медіацентрНовиниПодіїМатеріали для завантаженняВідеоБудьмо на зв’язкуБудьмо на зв’язкуЗв'язатися з намиКонтакти для запитів медичної інформації

Menu

Close

HomeEfficacyEffectivenessAcute Otitis MediaSafety & DosingSafety & DosingSafety ProfileDosing & AdministrationImmunogenicityAdherenceSupport & OrderSupport & OrderOrder Prevnar 13®EventsMaterialsVideosResourcesRequest a representative
AdherenceLate DosingContinue the fight against IPD by giving every dose of Prevnar 13®—on timeOne missed dose can have an impact on series completion*

Babies who receive a late dose of Prevnar 13® are UP TO 6X LESS LIKELY to complete the series than those who receive Prevnar 13® on time

Babies who receive doses 1-3 of Prevnar 13® on time are UP TO 6X MORE LIKELY to complete the series than those who receive Prevnar 13® late

Optum EHR Clinical Data (Q1 2020)*

The Optum® longitudinal clinical repository from Humedica is derived from healthcare provider organizations in the US that include more than 700 hospitals and 7000 clinics treating more than 105 million patients receiving care. The data are certified as de-identified by an independent statistical expert following HIPAA statistical de-identification rules, and managed according to Optum® customer data use agreements. Clinical claims and other medical administrative data are obtained from both inpatient and ambulatory electronic health records (EHR), practice management systems, and numerous other internal systems, and are processed, normalized, and standardized across the continuum of care, from both acute inpatient stays and outpatient visits. Optum® data elements include demographics; medications prescribed and administered; immunizations; allergies; lab results (including microbiology); vital signs and other observable measurements; clinical and inpatient stay administrative data; and coded diagnoses and procedures. In addition, Optum® uses natural language processing (NLP) computing technology to extract critical facts from physician notes into usable datasets. The NLP data provide detailed information regarding signs and symptoms, family history, disease-related scores (eg, RAPID3 for rheumatoid arthritis or CHADS2 for stroke risk), genetic testing, medication changes, and physician rationale behind prescribing decisions that might never be recorded in the EHR.1

Based on an Optum® Q1 2020 post hoc analysis of 2019 calendar year electronic healthcare records (EHR) of babies aged 24 months who received the Prevnar 13® third dose in 2019, derived from healthcare provider organizations covering 105 million adult and pediatric patients in the US.1Babies who receive their first dose at ≥7 months of age are not indicated for the fourth dose.2A dose was considered late if received after 119 days of age for dose 1, after 179 days of age for dose 2, and after 239 days of age for dose 3.1Missed well visitsWell-child visits continued to decline in 2021, putting 
babies at risk for vaccination delays and outbreaks of 
vaccine-preventable illness1,3-5

Study description: IQVIA weekly Dx US data for babies aged 0 to 24 months from 1/5/2019 to latest (rolling 4 weeks in 2021 versus the same 4-week period in 2019).1

The CDC and the AAP continue to stress the importance of well-child visits and vaccinations for babies and recommend that healthcare professionals2-6:
  • Promote well-child and vaccination visits to parents and caregivers   
  • Remind parents of their baby’s upcoming appointment, and recall those who missed appointments and CDC-recommended vaccinations
  • Educate eligible parents about the availability of publicly funded vaccines through the VFC program
AAP=American Academy of Pediatrics; CDC=Centers for Disease Control and Prevention; VFC=Vaccines for Children.While 83.8% of babies are receiving CDC-recommended dosing of Prevnar 13® nationally, vaccination rates vary among states7National vaccination rates by state based on the National Immunization Survey-Child.ReferencesLorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.In infants and young children, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is administered as a 4-dose series at 2, 4, 6, and 12 to 15 months of age. In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose.2Based on the CDC’s National Immunization Survey of babies aged 24 months and born in 2018. Data were collected in all 50 states, the District of Columbia, selected local areas, and territories.7Estimates for children born in 2018 are considered preliminary and will be finalized after the data for survey year 2021 are available.7  CDC=Centers for Disease Control and Prevention.Disparities in vaccination rates persist between privately insured babies and those who are uninsured or receiving Medicaid8 Next: Order Prevnar 13® LoadingReferences:Data on file. Pfizer Inc. New York, NY.Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.American Academy of Pediatrics. Guidance on providing pediatric well-care during COVID-19. Updated January 6, 2022. Accessed July 14, 2022. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/guidance-on-providing-pediatric-well-care-during-covid-19/. Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(19):591-593. Centers for Disease Control and Prevention. Information for pediatric healthcare providers. Updated December 30, 2020, Accessed July 14, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html.Pingali C, Yankey D, Elam-Evans LD, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 Years—United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(35):1183-1190.Centers for Disease Control and Prevention. Childhood vaccination coverage trend report: birth years 2011 through 2017. ChildVaxView website. Updated September 28, 2021. Accessed July 14, 2021. https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/interactive-reports/index.html.Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Sterrett N. Vaccination coverage by age 24 months among children born in 2017 and 2018—National Immunization Survey-Child, United States, 2018-2020. MMWR Morb Mortal Wkly Rep. 2021;70(41):1435-1440.

PREVNAR 13® is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2023 Pfizer Inc.


 

Safety & Dosing Effectiveness

See the demonstrated effectiveness of Prevnar 13®

Review nowLoading
Resources

Offer resources that may help improve adherence to the CDC-recommended vaccination schedule

Look nowLoading
Order from Pfizer Prime

To stock Prevnar 13®, call 1-800-666-7248 or click here

Order nowLoading
Quick links card

Слід повідомляти про небажані явища. Форми повідомлень та інформацію можна знайти за адресою https://aisf.dec.gov.ua/Account/LogOn

Акаунт PfizerProPfizerPro Account

Для отримання доступу до інших матеріалів, ресурсів і отримання повідомлень про препарати та вакцини, які просуває Pfizer

АвторизуватисяЗареєструватисяАкаунтВийти

Цей сайт призначений виключно для фахівців охорони здоров'я в Україні. Якщо ви є звичайним громадянином, який бажає отримати доступ до інформації про певний препарат, відвідайте http://www.drlz.com.ua

 

© Всі права захищено. Представництво "Пфайзер Експорт Бі.Ві" в Україні (2022)

 

PP-UNP-UKR-0019
Виключно для фахівців охорони здоров'я *

"Цей сайт розроблений виключно для використання з професійною метою фахівцями охорони здоров’я в Україні.

Pfizer не гарантує відповідність інформації та сервісів сайту цілям і очікуванням Користувача, його безперебійну та безпомилкову роботу.

Користувач самостійно і за свій рахунок зобов’язується врегулювати всі претензії третіх осіб, пов’язані з діями Користувача при користуванні цим сайтом.

Користувач самостійно несе повну відповідальність за належне використання матеріалів, розміщених на сайті, в тому числі: за використання таких матеріалів у відповідності з вимогами законодавства України, за дотримання авторських прав і прав третіх осіб, а також, за дотримання положень цієї Угоди.

Підтвердіть: "

Так Ні
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​